Clearview Cancer Institute

What Clearview Cancer Institute does

Clearview Cancer Institute (CCI) is a community-based outpatient oncology and hematology practice headquartered in Huntsville, Alabama, operating as Oncology Specialties, PC, a private professional corporation founded in 1984. The institute delivers comprehensive cancer care across 11+ clinic locations in North Alabama, anchored by a 110,000 sq ft flagship campus at the Russel Hill medical district and staffed by 27+ board-certified medical and radiation oncologists and 60+ advanced practice providers. Its service portfolio spans medical oncology, radiation oncology (added through the May 2026 integration of Alliance Cancer Care), hematology, diagnostic imaging, genetic and genomic testing, an on-site CLIA/COLA-certified laboratory, a URAC-, ACHC-, and NCODA-accredited specialty pharmacy, lung cancer screening, and a Phase I–IV clinical trials program that has helped evaluate over 40 FDA-approved oncology drugs.

CCI's business model is fee-for-service healthcare delivery, with revenue generated from specialist physician visits, chemotherapy/immunotherapy infusion, radiation therapy, imaging, lab services, specialty pharmacy dispensing, and sponsored clinical trial enrollment. Billing is insurance-based with co-pays collected at time of service; genetic and genomic testing are typically provided at little to no out-of-pocket cost via assistance programs. Customer acquisition combines physician referrals (fax and online portal channels from primary care and specialists), direct-to-consumer marketing through a website, social media, and 24/7 phone scheduling, and community engagement through support groups and volunteer programs. Research collaborations with Memorial Sloan Kettering, MD Anderson, Mayo Clinic, Johns Hopkins, Stanford, and HudsonAlpha Institute for Biotechnology differentiate the practice from typical community oncology centers, providing trial access normally limited to academic medical centers. The nonprofit Russel Hill Cancer Foundation (est. 2006) supports patient assistance, education, and research across 22 counties and 32+ healthcare provider partners.

Name

Clearview Cancer Institute

Legal name

Oncology Specialties, PC

Website

https://clearviewcancer.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

251–500 employees

Short description

Clearview Cancer Institute is a community-based outpatient oncology and hematology practice operating 11+ clinics across North Alabama, delivering chemotherapy, radiation therapy, imaging, specialty pharmacy, and Phase I–IV clinical trials to cancer and blood disorder patients.

Ownership category

akta.pro rank

Product category

Outpatient Oncology Care

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621), Other Ambulatory Health Care Services (6219)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Outpatient oncology care
• Cancer treatment services
• Radiation therapy services
• Clinical trial research
• Hematology treatment

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Oncology Services: Revenue from providing chemotherapy, biotherapy, immunotherapy, and hormone therapy treatments. Billed as specialist physician visits with co-pays collected at time of service. Insurance filed by the business office.
2. Laboratory Services: On-site CLIA and COLA certified laboratory providing hematology, clinical chemistries, immunodiagnostics, flow cytometry, and urinalysis testing. Lab revenue generated through standard medical billing.
3. Specialty Pharmacy: On-site specialty pharmacy at Russel Hill location filling oncology and hematology medications. Accredited by URAC and ACHC. Three convenient ways to get prescriptions: phone, email, and RxLocal app.
4. Clinical Trial Research: Revenue from pharmaceutical and biotechnology company sponsored clinical trials. Partnerships with Memorial Sloan Kettering, MD Anderson, Mayo Clinic, Johns Hopkins, and Stanford for research collaboration.
5. Radiation Oncology: Radiation therapy services following integration of Alliance Cancer Care as CCI's Radiation Oncology Division. External beam and internal radiation therapy treatments.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Clearview Cancer Institute delivers comprehensive outpatient cancer care across North Alabama, providing medical oncology, radiation oncology, hematology, diagnostic imaging, genetic and genomic testing, and an on-site specialty pharmacy. It also runs Phase I-IV clinical trials in partnership with major academic cancer centers, and surrounds treatment with support services including financial counseling, social work, support groups, dietitian services, and lung cancer screening.

Product overview

Clearview Cancer Institute is a community-based oncology practice serving North Alabama with a comprehensive outpatient cancer treatment center. The organization operates a platform-plus-services model centered on Medical Oncology and Radiation Oncology as core services, supported by Hematology, Diagnostic Imaging, Genetic/Genomic Testing, an accredited Pharmacy, and Clinical Trials (Phase I-IV). Additional services include Lung Cancer Screening, Social Services, Support Groups, Financial Counseling, Educational Classes, Dietician Services, and a Patient Portal. The institute has 11+ locations throughout Northern Alabama and partners with major academic cancer centers for research.

Differentiator

Problem solved

Functional benefit

Brands

• Alliance Cancer Care: Alliance Cancer Care joined Clearview Cancer Institute as its Radiation Oncology Division in May 2026, bringing radiation oncology physicians and care teams to CCI.

Products and services

• Medical Oncology
• Radiation Oncology
• Hematology
• Diagnostic Imaging
• Genetic Counseling
• Genetic Testing
• Genomic Testing
• Laboratory Services
• Specialty Pharmacy
• Phase I-IV Clinical Trials
• Lung Cancer Screening
• Social Services
• Support Groups
• Financial Services
• Educational Classes
• Dietician Services
• Outpatient Transfusion Services
• Patient Portal (Navigating Care)

Quantifiable outcome

• Over 40 FDA-approved drugs tested at CCI including Herceptin, Rituxan, Gazyva, Avastin, Gemzar, and Abraxane
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Alliance Cancer CarecoreStrategic or Co-development Partner · 1 May 2026Alliance Cancer Care joined CCI as its Radiation Oncology Division, bringing decades of experience in advanced radiation therapy to patients throughout North Alabama. The physicians and care teams now lead CCI's Radiation Oncology Division.
• Community Oncology AlliancecoreStrategic or Co-development Partner · 29 October 2025Community Oncology Alliance launched a Patient Advocacy Network chapter at Clearview Cancer Institute in Alabama to raise awareness of community cancer care and advocate for policies that improve access and quality of care.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerResearch partnership for clinical trial collaboration. Patients benefit from protocols developed at one of the world's leading cancer centers while receiving treatment close to home in North Alabama.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerAcademic partnership for clinical trial access and research collaboration. Provides patients access to cutting-edge treatments and research findings from the nation's top cancer center.
• Mayo Clinic Cancer CentercoreStrategic or Co-development PartnerClinical research partnership allowing CCI patients access to Mayo Clinic protocols and trials while being treated locally.
• The Sidney Kimmel Comprehensive Cancer Center of Johns HopkinscoreStrategic or Co-development PartnerResearch collaboration providing access to Johns Hopkins cancer research and clinical trial opportunities for North Alabama patients.
• Stanford University's Comprehensive Cancer InstitutecoreStrategic or Co-development PartnerAcademic partnership for clinical research and trial access, bringing Stanford's innovations to community oncology setting.
• HudsonAlpha Institute for BiotechnologycoreStrategic or Co-development PartnerClinical trials and research partnership for innovative cancer research. Supports genomic testing and personalized medicine approaches.
• Russel Hill Cancer FoundationcoreStrategic or Co-development Partner501(c)(3) nonprofit foundation supporting CCI through patient assistance, cancer education, and innovative research. Since 2006, serves 22 counties in North Alabama, partners with 32+ healthcare providers, and facilitates 32 grant programs. Supports clinical trials, support groups, Fit to Fight program with YMCA, and patient financial assistance.
• Huntsville HospitalcoreStrategic or Co-development PartnerPartnership with Huntsville Hospital for outpatient medical services including blood transfusions. Blackwell Medical Tower operated by CCI in partnership with Huntsville Hospital. CCI main campus located near Huntsville Hospital.
• YMCA (Fit to Fight Program)minorGTM or Marketing PartnerPartnership supporting the Fit to Fight exercise program for cancer patients, promoting physical activity during and after treatment.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• OneOncology: PE-backed (TPG) platform partnership of independent community oncology practices providing capital, technology, MSO services, and clinical research — a major incumbent competitor that aggregates practices that could otherwise be CCI peers.
• American Oncology Network: PE-backed alliance of community oncology practices offering shared services, clinical research, in-office dispensing pharmacy, and revenue cycle — a direct platform competitor for community oncology independence.
• The US Oncology Network (McKesson): Nation's largest network of community oncology practices (under McKesson), offering practice management, payer contracting, clinical trials, and technology infrastructure to affiliated oncologists — broader incumbent peer exerting consolidation pressure on CCI's market.
• Carolinas Cancer Group / Atrium Health Levine Cancer: Large regional oncology provider integrating medical and radiation oncology, clinical trials, and supportive services across the Carolinas — broader incumbent competitor with overlap in the Southeast regional catchment relative to North Alabama.
• Sarah Cannon Cancer Institute (HCA Healthcare): National community-based oncology research and treatment network operated within HCA hospital systems, including Phase I–IV clinical trials and comprehensive outpatient oncology — relevant incumbent peer exerting competitive and trial-recruitment pressure on CCI's catchment.

Direct peers

• Minnesota Oncology: Independent, physician-owned community oncology practice offering medical oncology, hematology, radiation oncology, and clinical research across multiple Twin Cities and greater Minnesota locations — directly comparable in independent multi-site community oncology.
• Highlands Oncology Group: Community oncology practice across Northwest Arkansas with medical oncology, radiation oncology, imaging, lab, pharmacy, and clinical trials — similar comprehensive outpatient platform anchored in a multi-clinic regional catchment.
• Florida Cancer Specialists & Research Institute: Community oncology powerhouse offering medical oncology, hematology, radiation oncology, genomic testing, and one of the largest community-based Phase I–IV clinical trial programs in the U.S. — directly comparable on full-service outpatient oncology plus a research-centric differentiator similar to CCI.
• Tennessee Oncology: Large community-based oncology practice operating multiple outpatient clinics across Tennessee with medical oncology, radiation oncology, clinical trials, and in-house ancillaries — a direct regional comparator to CCI's community-anchored, trial-enabled model.
• New York Cancer & Blood Specialists: Multi-location community oncology and hematology practice serving the New York region with medical oncology, radiation oncology, infusion, imaging, and clinical trials — comparable in scale, multi-clinic outpatient community oncology delivery model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ClearviewCancerInstitute
• Facebookfacebook.com/clearviewcancerinstitute
• LinkedInlinkedin.com/company/clearviewcancerinstitute
• Instagraminstagram.com/clearviewcancerinstitute
• Xx.com/ClearviewCancer

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearview Cancer Institute